Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis

RCT (n=204) found 73.5% of patients on 0.5mg twice daily and 75% on 1mg twice daily were in persistent remission vs 4.4% for placebo (p<0.001 for both placebo comparisons). Candidiasis occurred in 16.2% and 11.8% of patients given 0.5 and 1mg doses respectively.

Source:

Gastroenterology